A Preference Study of Two Pneumatic Compression Devices for Patients With Lower Limb Lymphedema

A Pilot Cross-Over Preference Study of Two Pneumatic Compression Devices for Patients With Lower Limb Lymphedema

This study will aim to undertake a preference evaluation comparing the Aria Health Aria Free™ to a competitor's device by assessing overall satisfaction and preference of the devices individually and in comparison to one another. Twenty (20) subjects will be enrolled on this study at one study site in Houston, Texas.

Study Overview

• Status: Completed
• Conditions: Lymphedema; Lymphedema, Secondary; Lymphedema, Lower Limb; Lymphedema of Leg; Lymphedema Primary
• Intervention / Treatment: Device: Aria Health Aria Free; Device: A Traditional PCD

Detailed Description

This research study is studying the preference of the compact Aria Health Aria Free™ Pneumatic Compression System ('Aria Free,' 'Aria') as a treatment for Lower Limb Lymphedema when compared to a traditional pneumatic compression device. A pneumatic compression device is also known as a 'PCD.' Both PCDs used in this study have been approved by United States Food and Drug Administration (FDA) for the treatment of lower limb lymphedema and are Code E0651 pneumatic compression devices, as defined by the Centers for Medicare & Medicaid Services (CMS) under The Healthcare Common Procedure Coding System (HCPCS) for Durable Medical Equipment (DME). Subjects participating in this study are asked to use each PCD for a short therapy session and then answer a series of questionnaires regarding their experience with the devices.

Participation in this study requires one clinic visit that will last about two (2) hours. At the beginning of the visit, the Investigator will ask each subject a series of questions to collect demographic data, and medical and pneumatic compression device usage history. The Investigator will then ask the subject to 'inspect' (touch and handle) the two PCDs used in this study and ask a few questions about the subject's opinion of the two devices based on this inspection. The Investigator will then guide the subject through completion of two (2) thirty (30) minute therapy sessions, one session using the Aria and the other session using the traditional PCD. The order in which the sessions are completed will be random, like the flip of a coin. Before and after each therapy session, the Investigator will complete a series of measurements and take photographs of the subject's lower limbs. The Investigator will also assess the subject's skin and tissue health after each intervention. Subjects will also be asked to complete questionnaires after each therapy session that will ask about subjective satisfaction with and preference between the two devices. Once the study visit has been completed, the subject will have completed the study and may return to his/her usual standard of care activities for treating his/her lower limb lymphedema.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77058
      • Lymphatic Solutions, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female patients who are ≥ 18 years, mentally able to understand and follow the instructions of the study personnel
• A diagnosis of unilateral or bilateral lower limb lymphedema
• A physician's prescription for use of a pneumatic compression device
• Able to provide written informed consent
• Patient can read and comprehend English
• Study leg must be within fit range of the Aria Free Garment (Ankle Max = 35cm/13.78in; Thigh Max = 80cm/34.49in)

Exclusion Criteria:

• Subject undergoing cancer treatment
• Subject has active lower limb wounds
• Subject is pregnant or trying to become pregnant
• History of pulmonary edema or decompensated congestive heart failure
• Subject has any condition in which increased venous and lymphatic return is undesirable
• Subject has inbuilt electrical stimulator, e.g., cardiac pacemaker
• Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)
• Severe peripheral artery disease (critical limb ischemia including ischemic rest pain, arterial wounds or gangrene)
• Active skin or limb infection/inflammatory disease (acute cellulitis, other uncontrolled skin or untreated inflammatory skin disease)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Aria Health Aria Free; An Aria Free therapy session on the study lower limb.	Device: Aria Health Aria Free; An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.
ACTIVE_COMPARATOR: Traditional PCD; A therapy session using the traditional PCD on the study lower limb.	Device: A Traditional PCD; An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Satisfaction and Preference	The primary outcome of this study is to compare levels of subjective ratings of satisfaction and preference measurements after completed sessions with Aria Free and the traditional PCD devices. Each session is 30 minutes in duration. Subjective measures for each device will use an 11-point Likert Scale where a score of 10 is considered very favorable and a score of 0 is very unfavorable.	Satisfaction and Preference ratings will be assessed during the only study visit: Visit 1/Day 1.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Limb Volume Measurements	The Principal Investigator will collect pre and post intervention circumferential limb measurements for each subject and these measurements will be used in a truncated cone formula to calculate total limb volume. Each intervention is 30 minutes in duration. The pre and post total limb volume measurements will be compared and assessed for change.	Limb volume measurements will be collected during the only study visit: Visit 1/Day 1.
Clinician's Skin and Tissue Health Assessment	The Principal Investigator will assess the skin and tissue health of the study lower limb after each intervention. Each intervention is 30 minutes in duration. Twenty observations are listed for the Investigator to document 'Yes' or 'No' if any of the observations are present or not, respectively, during the lower limb physical exam.	The skin and tissue will be assessed during the only study visit: Visit 1/Day 1.

Collaborators and Investigators

• Sponsor: ResMed
• Collaborators: Lymphatic Solutions, LLC
• Investigators: Principal Investigator: Denise M Baylor, CLT-LANA, Lymphatic Solutions, Owner

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 11, 2022
• Primary Completion (ACTUAL): July 30, 2022
• Study Completion (ACTUAL): July 30, 2022

Study Registration Dates

• First Submitted: July 18, 2022
• First Submitted That Met QC Criteria: August 1, 2022
• First Posted (ACTUAL): August 3, 2022

Study Record Updates

• Last Update Posted (ACTUAL): September 15, 2022
• Last Update Submitted That Met QC Criteria: September 13, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Pneumatic Compression Device
• Additional Relevant MeSH Terms: Lymphatic Diseases; Lymphedema
• Other Study ID Numbers: AF22-04-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual Participant Data available will not be shared with other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No